Table 1.

Test performance required to achieve a specific PPV in low-risk and high-risk populations

Required test specificity
Annual incidence of ovarian cancer
Women aged 55–59 from the general populationaWomen aged 55–59 with BRCA mutationsb
Test sensitivityPPVPPVPPVPPVPPVPPV
5%10%20%5%10%20%
0.50.98700.99380.99730.59280.80710.9143
0.60.98440.99260.99670.51140.76850.8971
0.70.98180.99140.99620.42990.73000.8800
0.80.97910.99010.99560.34850.69140.8628
0.90.97650.98890.99510.26710.65280.8457
0.950.97520.98830.99480.22630.63350.8371
0.9750.97460.98800.99460.20600.62390.8328
0.990.97420.98780.99460.19380.61810.8303
0.9950.97410.98770.99450.18970.61620.8294
10.97390.98770.99450.18560.61420.8286
  • aBased on rates for white women 55 to 59 years old in SEER17.

  • bAssuming 30-fold increased risk compared with the standard risk in that age group.